Conceptual issues in the analysis of cost data within cluster randomized trials

Area of Science:

• Health Economics
• Biostatistics
• Health Services Research

Background:

• Cluster randomized controlled trials (RCTs) are increasingly utilized for economic evaluations in social, educational, and healthcare interventions.
• Existing methodological guidelines for RCTs are fragmented across disciplines and lack specific guidance for analyzing cost data.
• Incomplete guidelines pose challenges for health service researchers, particularly regarding the calculation of confidence intervals for cost data.

Purpose of the Study:

• To highlight the methodological issues specific to the analysis of cost data in cluster RCTs.
• To emphasize the need for collaboration between trialists and health economists in designing economic evaluations.
• To propose a framework for facilitating collaboration and addressing design problems in cluster-based economic evaluations.

Main Methods:

• Review of existing methodological research on cluster RCTs and economic evaluations.
• Identification of specific challenges in analyzing cost data within cluster RCTs, particularly concerning confidence intervals.
• Development of a conceptual framework to guide the design and analysis of cluster-based economic evaluations.

Main Results:

• Current guidelines for cluster RCTs do not adequately address the unique methodological issues in analyzing cost data.
• The calculation of confidence intervals for costs in health care priority setting presents significant challenges.
• A lack of collaboration between trialists and health economists can lead to poorly designed economic evaluations.

Conclusions:

• Enhanced collaboration between trialists and health economists is essential for improving the design and analysis of cluster-based economic evaluations.
• Specific attention must be paid to the methodological challenges of cost data analysis, including confidence interval calculation.
• Addressing these issues is critical to avoid poorly designed trials and ensure reliable evidence for health care priority setting.